Clinical Study of Atomized Inhalation of Isoniazid in the Treatment of Primary Treatment Germ Positive Cavity-type Pulmonary Tuberculosis
Objective:To investigate the effect of atomized inhalation of Isoniazid in the treatment of primary treatment germ positive cavity-type pulmonary tuberculosis.Method:Forty-five patients with primary treatment germ positive cavity-type pulmonary tuberculosis admitted to Pingnan People's Hospital from July 2021 to December 2022 were selected as the study objects.They were divided into conventional group(n=23)and atomized group(n=22)according to random number table method.The conventional group was given conventional anti-tuberculosis treatment,and the atomizing group was given Isoniazid atomizing inhalation therapy on the basis of the control group.Bacteria turning negative condition,cavity closure condition after 2 months and 6 months of treatment and adverse reactions were compared between the two groups.Result:After 2 months of treatment,the sputum conversion negative rate of atomization group was higher than that of conventional group,and the average time of sputum conversion negative was earlier than that of control group,the differences were statistically significant(P<0.05).The cavity closure rate after 2 months and 6 months in the atomization group was higher than that in the conventional group,and the difference was statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Isoniazid nebulization assisted conventional anti-tuberculosis therapy has a higher sputum negative conversion rate,faster sputum negative conversion,better lesion absorption,and better treatment effect with good safety.
国家科技期刊平台
NSTL
万方数据
维普
